Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|April 27, 2011
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growthRob C Roovers, Maria J W D Vosjan, Toon Laeremans, et al.
Clinical Immunology (Orlando, Fla.)|July 5, 2016
Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applicationsRenée C G de Bruin, Sinéad M Lougheed, Liza van der Kruk, et al.
Expert Opinion on Biological Therapy|July 10, 2019
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysisPieter Fokko van Loo, Basav N Hangalapura, Soley Thordardottir, et al.
Scientific Reports|August 4, 2022
Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodiesJord C Stam, Steven de Maat, Dorien de Jong, et al.
Iscience|December 4, 2024
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engagerLisa A King, Myrthe Veth, Victoria Iglesias-Guimarais, et al.
Cancer Immunology Research|November 12, 2020
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell MalignanciesIris de Weerdt, Roeland Lameris, George L Scheffer, et al.
Cell Reports. Medicine|March 3, 2023
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignanciesRoeland Lameris, Jurjen M Ruben, Victoria Iglesias-Guimarais, et al.
Cancer Immunology Research|June 27, 2023
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing TumorsLisa A King, Elisa C Toffoli, Myrthe Veth, et al.
Oncoimmunology|January 4, 2018
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cellsRenée C G de Bruin, John P Veluchamy, Sinéad M Lougheed, et al.
Nature Communications|October 20, 2018
The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomersLaura C Zanetti-Domingues, Dimitrios Korovesis, Sarah R Needham, et al.
Pageof 4